Resources
Menu
Close
Resources
Contact us
Oral solid dose
Sterile injectables
Antibody-drug conjugates
Tech transfer
OSD manufacturing
SI manufacturing
ADC manufacturing
Careers
Leadership team
Sustainability
IP protection
Expert insights
ADC Manufacturing
Antibody-drug conjugate excellence from Pearl River and North Creek
Pfizer CentreOne helps deliver confidence in every conjugate through two extensive facilities dedicated to antibody-drug conjugate manufacturing. At North Creek, WA, 51,000 square feet of purpose-built space enables mammalian antibody and ADC manufacturing with advanced single-use technologies and a highly skilled team. Leveraging approximately 24,000 square feet of ADC manufacturing space specifically designed for highly potent and cytotoxic drug processing, the Pearl River, NY, site empowers you to bring life-changing ADC therapies to patients faster.
Download brochure
Pearl River's capabilities at a glance
In-house QC labs for in-process, release and stability testing
Leaders in ADC manufacturing with a legacy of success
Pearl River’s team of experienced scientists possesses decades
of expertise in ADCs. With a wealth of knowledge in the production and scale-up of antibody and protein technologies, they offer an unparalleled understanding of the complexities of bringing these
life-changing therapies to market.
Pfizer's experience producing the world's first commercially approved ADC (Mylotarg™) provides the foundation for our comprehensive solutions and unwavering commitment to your success.
Time is life
Our global network of scientists, regulatory experts, and analytical and quality control engineers is dedicated to streamlining your ADC’s path to market.
By optimizing processes and leveraging our expertise, we reduce wait times for manufacturing suite access, accelerate process scale-up and minimize process cycle times, helping to ensure efficient and timely delivery of your life-changing therapy.
Explore our sites
Pearl River, NY
1/2
North Creek, WA
2/2
Success
Thank you, your submission has been received!
Latest marketing updates
Let’s stay in touch
Pfizer CentreOne would like to send you information which we believe may be of value to you and relevant to your work. If you would like to receive such information, please tick the box below.
BY TICKING THE BOX AND CLICKING “LET’S COLLABORATE” BELOW, I CONSENT TO RECEIVING THOUGHT LEADERSHIP, INDUSTRY NEWS, AND INVITATIONS BY EMAIL OR OTHER ELECTRONIC MEANS, WHICH PFIZER CENTREONE BELIEVES MAY BE OF VALUE TO ME, RELEVANT TO MY WORK AND TAILORED TO MY PROFESSIONAL PROFILE AND INTERESTS. THIS MAY INCLUDE PROMOTIONAL INFORMATION ON PRODUCTS, SERVICES AND EVENTS PROVIDED OR ORGANIZED BY PFIZER CENTREONE.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Let's Collaborate
A CMO for therapies that define legacies
Follow us
Latest marketing updates
Sign up
© 2025 Pfizer Inc. All rights reserved. Pfizer CentreOne is a registered trademark of Pfizer Inc. Privacy Policy | Terms of Use